Alphamab Oncology disclosed in a Next Day Disclosure Return to the Hong Kong Stock Exchange that it repurchased 220,000 ordinary shares on 8 September 2026. The on-exchange buyback was executed at prices ranging between HKD 8.345 and HKD 8.530, with a volume-weighted average of HKD 8.41 per share, for a total consideration of HKD 1.85 million.

Following the transaction, the company’s treasury share balance increased to 6.72 million, while outstanding issued shares (excluding treasury shares) declined to 967.67 million. The repurchased amount represents 0.0227% of the company’s issued share capital prior to the transaction. Total shares in issue remain unchanged at 974.38 million, as the repurchased shares are being held in treasury and have not been cancelled.

The purchase forms part of Alphamab Oncology’s buyback mandate approved on 12 June 2026, which authorises repurchases of up to 96.85 million shares. Including the latest trade, the company has bought back 0.84 million shares year-to-date, equivalent to 0.0868% of the shares outstanding at the time the mandate was granted.

In accordance with Main Board Rule 10.06(3)(a), Alphamab Oncology is subject to a moratorium on issuing new shares or transferring treasury shares until 8 October 2026.